Finnish Institute to Use Labcyte Tech to Enhance Cancer Testing Studies | GenomeWeb

NEW YORK (GenomeWeb News) – Labcyte said today that the Institute for Molecular Medicine Finland, known as FIMM, will use Labcyte's acoustic liquid handling technology in its small molecule-based personalized cancer medicine programs, under a new collaboration.

Helsinki-based FIMM has already used Labcyte's acoustic liquid handling technology to generate better data and to reduce the costs of its small-molecule screening for the past three years, Labcyte CEO Mark Fischer-Colbrie said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.